El Bissati, Kamal
Zhou, Ying
Paulillo, Sara Maria
Raman, Senthil Kumar
Karch, Christopher P.
Roberts, Craig W. http://orcid.org/0000-0002-0653-835X
Lanar, David E.
Reed, Steve
Fox, Chris
Carter, Darrick http://orcid.org/0000-0001-5901-3402
Alexander, Jeff
Sette, Alessandro
Sidney, John
Lorenzi, Hernan
Begeman, Ian J.
Burkhard, Peter
McLeod, Rima
Article History
Received: 15 November 2016
Revised: 20 June 2017
Accepted: 21 June 2017
First Online: 5 September 2017
Competing interests
: P.B. has an interest in Alpha-O Peptides, a company with a focus on SAPN. R.M. agreed to be on the scientific advisory board for this company. This company has patents or patents pending on relevant technology. The following authors (R.M., K.E.B., Y.Z., P.B., J.A., A.S., J.S., S.R., C.F., D.C., C.W.R.) have submitted a patent application covering much of our vaccine work over the past years, including the work described in this manuscript. This is with the ultimate goal of making a vaccine that can be moved into the clinic to prevent suffering from human toxoplasmosis, so that this vaccine can be widely available for humans. The other authors declare no competing interests. Funding sources had no influence in study design; nor in the collection, analysis and interpretation of data; nor in the writing of this report; and no interest in the decision to submit the paper for publication.